Chromatin rewiring of ß-globin and MYC enhancers by TGF-ß1 drives defective erythropoiesis.
Chromatin rewiring of ß-globin and MYC enhancers by TGF-ß1 drives defective erythropoiesis. Nat Commun. 2026 May 13; 17(1).
PMID: 42129196
Elevated Clonal Hematopoiesis in 9/11 First Responders Has Distinct Age-related Patterns and Relies on IL1RAP for Clonal Expansion.
Elevated Clonal Hematopoiesis in 9/11 First Responders Has Distinct Age-related Patterns and Relies on IL1RAP for Clonal Expansion. Cancer Discov. 2025 Dec 02; 15(12):2468-2484.
PMID: 41031953
Splicing of erythroid transcription factor is associated with therapeutic response in myelodysplastic syndromes.
Splicing of erythroid transcription factor is associated with therapeutic response in myelodysplastic syndromes. J Clin Invest. 2025 Jul 01; 135(13).
PMID: 40424086
Enrichment of CD4+ and CD8+ T lymphocytes with a column-free flow-based device for clinical cell manufacturing.
Enrichment of CD4+ and CD8+ T lymphocytes with a column-free flow-based device for clinical cell manufacturing. Cytotherapy. 2025 Apr; 27(4):534-543.
PMID: 39891633
PU.1-Dependent Enhancer Inhibition Separates Tet2-Deficient Hematopoiesis from Malignant Transformation.
PU.1-Dependent Enhancer Inhibition Separates Tet2-Deficient Hematopoiesis from Malignant Transformation. Blood Cancer Discov. 2022 09 06; 3(5):444-467.
PMID: 35820129
Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations.
Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations. Elife. 2022 08 30; 11.
PMID: 36040792
BET inhibitors enhance embryonic and fetal globin expression in erythroleukemia cell lines.
BET inhibitors enhance embryonic and fetal globin expression in erythroleukemia cell lines. Haematologica. 2021 12 01; 106(12):3223-3227.
PMID: 34435481
The demise of islet allotransplantation in the United States: A call for an urgent regulatory update.
The demise of islet allotransplantation in the United States: A call for an urgent regulatory update. Am J Transplant. 2021 04; 21(4):1365-1375.
PMID: 33251712
Epigenetic modifiers in normal and aberrent erythropoeisis.
Epigenetic modifiers in normal and aberrent erythropoeisis. Semin Hematol. 2021 01; 58(1):15-26.
PMID: 33509439
Navigating Dilemmas in Treatment Choice: Our Approach to Supplemental Apheresis Prior to Enrollment in Early- Phase Cellular Therapy Clinical Trials.
Navigating Dilemmas in Treatment Choice: Our Approach to Supplemental Apheresis Prior to Enrollment in Early- Phase Cellular Therapy Clinical Trials. Transplant Cell Ther. 2021 02; 27(2):105-107.
PMID: 33781544